Page 154 - CW E-Magazine (15-7-2025)

Pharmaceuticals

SHARE PURCHASE AGREEMENT

Torrent to acquire additional 2.41% stake in JB

Chemicals for Rs. 620-crore

Ahmedabad-based Torrent Pharma- This additional stake pur-
ceuticals has signed a share purchase chase follows Torrent Pharma’s
agreement to acquire an additional announcement on June 30,
2.41% stake in J.B. Chemicals & when it said it would acquire
Pharmaceuticals Ltd from employees a majority 46.39% stake in JB
for a total cash consideration of Chemicals from its promoter,
Rs. 620-crore, or Rs. 1,600 per share, Tau Investment Holdings,
the company said in an exchange fi ling. for Rs. 11,917-crore. The
deal is set to become India’s
The acquisition involves 38.75-lakh second-largest pharma deal
equity shares, which the employees are ever, after Sun Pharma’s
selling after exercising their stock op- a fi ling with stock exchanges. Torrent 2015 acquisition of Ranbaxy. Follow-
tions. The transaction will be comple- also said it may acquire the remaining ing the acquisition, JB Chemicals will
ted after Torrent fi nalises its acquisition 0.39% stake (around 6.24-lakh shares) be merged into Torrent, with share-
of a controlling stake in J.B. Chemi- from other employees at the same price, holders of JB Pharma receiving 51
cals, subject to shareholder and regu- and would disclose any such deal shares of Torrent for every 100 shares
latory approvals, the company said in separately. held.

Alembic Pharma buys Utility Therapeutics for $12-mn
Vadodara-based Alembic Pharma- Alembic will begin commerciali- to the branded pharmaceutical market
ceuticals, through its US arm, Alembic sation of Utility’s Pivya (pivmethecil- with a near-term commercial launch.”
Pharmaceuticals Inc, has acquired lam) for the treatment of uncomplicated
Utility Therapeutics Ltd. in a $12-mn UTIs. Pivya was approved by the US Mr. Craig Salmon, President of
deal to strengthen its presence in the regulator in April 2024. Alembic Pharmaceuticals Inc, said,
US market. “The acquisition of Utility broadens
Mr. Pranav Amin, Managing Direc- Alembic Inc’s footprint beyond generic
Utility Therapeutics specialises in the tor of Alembic Pharmaceuticals said, pharmaceuticals and will allow Alem-
development and approval of branded the acquisition was a strategic entry into bic to build out its capabilities in the
pharmaceutical products for the treat- the specialty and branded prescription large US branded pharmaceutical
ment of urinary tract infections (UTIs). products, that would “give us exposure market”.

Lupin launches generic Ipratropium nasal spray

in US market

Lupin said it has launched Ipratro- nasal sprays of the same strengths, it for the symptomatic relief of rhinor-
pium Bromide nasal spray, used in treat- added. rhea associated with the common cold
ment of runny nose, in the US market. or seasonal allergic rhinitis for adults
Lupin said Ipratropium Bromide and children aged 5 years and older,
The Ipratropium Bromide nasal nasal spray 0.03% is indicated for the it added.
solution launched in the US is of symptomatic relief of rhinorrhea asso-
strengths 0.03% and 0.06%, the ciated with allergic and non-allergic Citing IQVIA MAT May 2025
Mumbai-based fi rm said in a regulatory perennial rhinitis in adults and children data, the company said ‘Atrovent’ had
fi ling. The drugs are bioequivalent to aged 6 years and older. Ipratropium estimated annual sales of $63-mn in
Boehringer Ingelheim’s ‘Atrovent’ Bromide nasal spray 0.06% is indicated the US.

154 Chemical Weekly July 15, 2025

Contents Index to Advertisers Index to Products Advertised